International Journal of Hematology and Oncology
2023, Vol 33, Num 4 Page(s): 080-085
FLUDARABINE BASED CHEMOTHERAPY IN CHRONIC LYMPHOCYTIC LEUKEMIA/LYMPHOMA
FEVZİ ALTUNTAŞ1, BÜLENT ESER1, ÖZLEM CANÖZ1, ÖZLEM ER1, METİN ÖZKAN1, SERDAR ŞIVGIN1, MUSTAFA ÇETİN1, ALİ ÜNAL1
Erciyes Üniv. Tıp Fak. Dedeman Hastanesi, Hematoloji-Onkoloji BD, KAYSERİ
Keywords: chronic lymphocytic leukemia/lymphoma, fludarafludarabine based bine, chemotherapy
Forty-seven patients chronic lymphocytic leukemia (CLL) (n=31) and small lymphocytic lymphoma (SLL) (n=16) treated with fludarabine and fludarabine+mitoxantrone+ dexamethasone (FND) regimen between 1997-2002 in our institute were retrospectively analyzed. Twenty-two patients were previously untreated (group-I) and 25 patients were previously treated and had refractory or relapsed disease (group-II). Fludarabine was administered in 16 patients (group I/II=6/10). Thirty-one patients were treated with a regimen of FND (group I/II=16/15). Treatment was repeated at 4-week intervals for maximum 6 courses. The median follow-up was 22 months (range: 5-63). The overall response rates were 72.8 % and 56% in group- I and group-II, respectively (p<0.001). Progression-free survival (PFS) rate was higher in group-I but not statistically significant compared with group-II (p>0.05). In patients treated with fludarabine, PFS rate was compared with FND not significant statistically (p>0.05). FND was associated with a substantially higher rate of grade II-IV neutropenia than fludarabine. Although both regimens were associated with high response rates in patients with previously untreated, FND was highly effective in patients with refractory or relapsed disease but it was more toxic than fludarabine.
FEVZİ ALTUNTAŞ1, BÜLENT ESER1, ÖZLEM CANÖZ1, ÖZLEM ER1, METİN ÖZKAN1, SERDAR ŞIVGIN1, MUSTAFA ÇETİN1, ALİ ÜNAL1
Erciyes Üniv. Tıp Fak. Dedeman Hastanesi, Hematoloji-Onkoloji BD, KAYSERİ
Keywords: chronic lymphocytic leukemia/lymphoma, fludarafludarabine based bine, chemotherapy
Forty-seven patients chronic lymphocytic leukemia (CLL) (n=31) and small lymphocytic lymphoma (SLL) (n=16) treated with fludarabine and fludarabine+mitoxantrone+ dexamethasone (FND) regimen between 1997-2002 in our institute were retrospectively analyzed. Twenty-two patients were previously untreated (group-I) and 25 patients were previously treated and had refractory or relapsed disease (group-II). Fludarabine was administered in 16 patients (group I/II=6/10). Thirty-one patients were treated with a regimen of FND (group I/II=16/15). Treatment was repeated at 4-week intervals for maximum 6 courses. The median follow-up was 22 months (range: 5-63). The overall response rates were 72.8 % and 56% in group- I and group-II, respectively (p<0.001). Progression-free survival (PFS) rate was higher in group-I but not statistically significant compared with group-II (p>0.05). In patients treated with fludarabine, PFS rate was compared with FND not significant statistically (p>0.05). FND was associated with a substantially higher rate of grade II-IV neutropenia than fludarabine. Although both regimens were associated with high response rates in patients with previously untreated, FND was highly effective in patients with refractory or relapsed disease but it was more toxic than fludarabine.